WAYLAND, Mass., Feb. 13 -- Candela Corp. has received FDA clearance from the US Food and Drug Administration to market the Vbeam pulsed dye laser for treatment of periorbital wrinkles.
"We're excited that this new clearance validates the anecdotal feedback we've been receiving virtually since the Vbeam's introduction two years ago -- namely, that this laser has exceptional utility in the treatment of periorbital wrinkles," said Gerard E. Puorro, Candela president and CEO.
"The FDA clearance can increase physicians' confidence in the Vbeam not only as an important laser for the medical treatment of vascular lesions, but as a laser for periorbital wrinkle reduction. We feel this new clearance confirms the Vbeam's versatility and utility as a staple in the physician's office," Puorro said.